Proportion of patients with improvement, stability, or deterioration of dyspnea, %FVC, %DLco, and radiologic imaging between the first and last clinic visits according to the ANCA results. (A) Dyspnea severity evolution as per the Medical Research Council dyspnea scale. (B) Evolution of the percentage of the predicted FVC. (C) Evolution of the percentage of the predicted DLco. (D) Evolution of interstitial lung disease on pulmonary HRCT. Improvement is shown in green, stability in orange, and deterioration in red. aImprovement or deterioration of %FVC was defined as an increase or decrease of ≥10% in its predicted value. bThe improvement or deterioration of %DLco was defined as an increase or decrease of ≥15% in its predicted value. Stability was defined as variations in both %FVC <10% and %DLco <15% between the first and last clinic visit. cThe evolution of HRCT was based on the opinion of a pulmonary radiologist with an interstitial lung disease specialist. ANCA, antineutrophil cytoplasmic autoantibody; DLco, diffusion capacity of the lungs for carbon monoxide; FVC, functional vital capacity; HRCT, high‐resolution computer tomography.